C19 SARS-CoV-2-specific T cells in the infected nasel epithelium
C19 SARS-CoV-2-specific T cells in the infected nasel epithelium
批准号:
10430281
负责人:
David M Koelle
金额:
$22.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-06-15 至 2024-05-31
关键词:
2019-nCoVACE2Acute Respiratory Distress SyndromeAdjuvantAnatomyAntibody ResponseAntigensAntiviral ResponseApplications GrantsAreaAttenuatedAvidityCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCOVID-19COVID-19 vaccineCell CommunicationCell Culture TechniquesCell DeathCell LineCellsComplexContainmentCuretteDataDaughterDiseaseEnvironmentEpithelialEpithelial CellsEpitopesEquilibriumFollow-Up StudiesGenesGeneticHarvestHomeHumanImmuneImmune EvasionImmune responseIn VitroInfectionInferior nasal conchaInflammatoryInfluenza vaccinationLower respiratory tract structureMeasurementMeasuresMedicalMethodsModelingNasal EpitheliumNasal cavityNational Institute of Allergy and Infectious DiseaseNoseNucleic AcidsOrganOrganoidsOutcomeOutputPatientsPeptidesPeripheral Blood Mononuclear CellPersonsPhysiologicalPneumoniaProductionProteinsRNAReagentResearch PersonnelResourcesRespiratory SystemSARS-CoV-2 infectionSiteSpecificitySpeedSymptomsSystemT cell responseT-LymphocyteTMPRSS2 geneTechnologyTimeTissuesTriad Acrylic ResinUpper respiratory tractVaccinationVaccinesViralViral ProteinsViral VectorVirusVirus ReplicationWorkacquired immunityairway epitheliumbiobankcohortcytokinecytotoxicityeffector T cellexperiencein vivolaboratory experiencemutantneutralizing antibodypathogenresponsesevere COVID-19toolvaccine candidatevaccine platformvirology
中文摘要
总结
对SARS-CoV-2感染的获得性抗原特异性免疫反应可能是
确定COVID-19的结果以及疫苗接种的有效性和持久性。cd 4 T细胞
需要帮助才能产生持久的、强烈的抗体反应。主要候选疫苗包括
- 也可以诱导CD 8 T细胞的一些形式,如病毒载体和核酸,以及
其它形式如佐剂化蛋白质不能。抗病毒药物的有力证据
病毒特异性CD 8 T细胞的作用可能会使平衡向有利于CD 8诱导疫苗的方向倾斜
平台本探索性R21对T细胞对SARS-CoV-2应答的目的1和目的2
分别涉及CD 8和CD 4 T细胞应答。上下呼吸道
上皮是SARS-CoV-2的主要靶组织。鼻上皮特别是
富含病毒进入所需的宿主分子ACE 2和TMPRSS 2的表达。我们利用
合作研究者Abuzeid在获取鼻细胞和扩大原发性鼻肿瘤方面的经验
上皮细胞(HNEpC)和合作者Greninger在BSL 3病毒学和
定量RNA测量以创建研究T细胞感染的上皮细胞的系统
体外相互作用我们利用我们的大型COVID-19生物库、实验室内经验和其他NIAID
资源,以产生功能上无限量的高亲和力SARS-CoV-2特异性CD 8
和具有精确已知的HLA限制和确定的肽靶的CD 4 T细胞。感染
HNEpC将被仔细表征和优化。然后我们将测量T细胞效应子
功能包括杀死感染的细胞、减少病毒子代输出和细胞因子
release.在后续研究中,我们希望利用SARS-CoV-2基因系统,
在候选免疫逃避基因中定义突变体,并将我们的研究扩展到下呼吸道
束细胞和类器官。总的来说,我们努力模拟免疫系统之间的重要相互作用。
细胞和SARS-CoV-2感染的呼吸道。
相关性
疫苗可能需要引发SARS-CoV-2特异性T细胞,这些T细胞可以快速识别SARS-CoV-2。
2-特异性感染上呼吸道上皮细胞,并关闭其生产
子代病毒,以限制患者体内感染和症状的进展,以及
减少可能传染他人的传染性病毒的散播。在R21补助金中
应用,我们将使用既定的工作方法来隔离大量的纯SARS-
来自康复者的CoV-2特异性T细胞并研究其发挥抗病毒作用的能力
使用细胞培养物的细胞,这些细胞排列在鼻腔中,通常在COVID期间被感染,
19.
英文摘要
Summary
The acquired, antigen-specific immune response to SARS-CoV-2-infection is likely central to
determining the outcome of COVID-19 and the efficacy and durability of vaccination. CD4 T cell
help is required for lasting, avid antibody responses. The leading vaccine candidates include
some formats that can also induce CD8 T cells, such as viral vectors and nucleic acids, and
other formats such as adjuvanted protein that cannot. Compelling evidence for an antiviral
effects of virus-specific CD8 T cells could tilt the balance in favor of CD8-eliciting vaccine
platforms. Aim 1 and Aim 2 of this exploratory R21 on the T cell response to SARS-CoV-2
concern CD8- and CD4 T cell responses, respectively. Upper and lower airway respiratory
epithelium are the primary target tissues for SARS-CoV-2. The nasal epithelium is particularly
rich in expression of ACE2 and TMPRSS2, host molecules required for viral entry. We leverage
Co-Investigator Abuzeid’s experience in harvesting nasal cells and expanding primary nasal
epithelial cells (HNEpC) and Collaborator Greninger’s expertise in BSL3 virology and
quantitative RNA measurement to create systems to study T cell-infected epithelial cell
interactions in vitro. We use our large COVID-19 biobank, in-lab experience, and other NIAID
resources to generate functionally unlimited amounts of highly avid SARS-CoV-2-specific CD8
and CD4 T cells with precisely known HLA restriction and defined peptide targets. Infection of
HNEpC will be carefully characterized and optimized. We will then measure T cell effector
functions including the killing of infected cells, reduction of viral progeny output, and cytokine
release. In follow-up studies, we hope to leverage SARS-CoV-2 genetic systems to make
defined mutants in candidate immune evasion genes and extend our studies to lower respiratory
tract cells and organoids. Overall, we strive to model important interactions between immune
cells and the SARS-CoV-2 infected respiratory tract.
Relevance
Vaccines may need to elicit SARS-CoV-2 specific T cells that can quickly recognize SARS-CoV-
2-specific infected upper respiratory tract epithelial cells and shut down their production of
progeny virus, to both limit the progression of infection and symptoms within patients, and
reduce the shedding of infectious virus that may infect other persons. In this R21 grant
application, we will use established, working methods to isolate large quantities of pure SARS-
CoV-2-specific T cells from recovered persons and study their ability to exert anti-viral effects
using cell cultures of the cells that line the nasal cavity that are normally infected during COVID-
19.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1172/jci.insight.158126
发表时间:
2022-03-22
期刊:
JCI insight
影响因子:
8
作者:
[Jing L, Wu X, Krist MP, Hsiang TY, Campbell VL, McClurkan CL, Favors SM, Hemingway LA, Godornes C, Tong DQ, Selke S, LeClair AC, Pyo CW, Geraghty DE, Laing KJ, Wald A, Gale M Jr, Koelle DM]
通讯作者:
Koelle DM
DOI:
10.1182/bloodadvances.2022009164
发表时间:
2023-09-12
期刊:
Blood advances
影响因子:
7.5
作者:
[Ujjani C, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien S, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling A, Tu B, Sorensen T, Launchbury K, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA]
通讯作者:
Thompson PA
C19 SARS-CoV-2-specific T cells in the infected nasel epithelium
-
批准号:10285229
-
项目类别:
-
资助金额:$26.47万
-
财政年份:2021
-
负责人:David M Koelle
-
依托单位:
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma
-
批准号:10380819
-
项目类别:
-
资助金额:$45.4万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Specific T and B cell responses to candidate Treponema pallidum outer membrane protein vaccine antigens
-
批准号:10671517
-
项目类别:
-
资助金额:$63.87万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma
-
批准号:10629192
-
项目类别:
-
资助金额:$42.33万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Cutaneous pathogen-specific tissue resident memory T cells in human aging
-
批准号:10624283
-
项目类别:
-
资助金额:$55.87万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Cutaneous pathogen-specific tissue resident memory T cells in human aging
-
批准号:10186853
-
项目类别:
-
资助金额:$17.26万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Cutaneous pathogen-specific tissue resident memory T cells in human aging
-
批准号:9923517
-
项目类别:
-
资助金额:$56.33万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Cutaneous pathogen-specific tissue resident memory T cells in human aging
-
批准号:10228544
-
项目类别:
-
资助金额:$56.18万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Specific T and B cell responses to candidate Treponema pallidum outer membrane protein vaccine antigens
-
批准号:10219125
-
项目类别:
-
资助金额:$75.64万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Cutaneous pathogen-specific tissue resident memory T cells in human aging
-
批准号:10468080
-
项目类别:
-
资助金额:$55.88万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Specific T and B cell responses to candidate Treponema pallidum outer membrane protein vaccine antigens
-
批准号:10461741
-
项目类别:
-
资助金额:$67.05万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Specific T and B cell responses to candidate Treponema pallidum outer membrane protein vaccine antigens
-
批准号:9982776
-
项目类别:
-
资助金额:$69.39万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Cutaneous Pathogen-Specific Tissue Resident Memory T Cells in Human Aging
-
批准号:10118463
-
项目类别:
-
资助金额:$39.62万
-
财政年份:2019
-
负责人:David M Koelle
-
依托单位:
Genomic systems approach to measure HSV-1-specific T-cell dominance in humans
-
批准号:8775628
-
项目类别:
-
资助金额:$43.5万
-
财政年份:2011
-
负责人:David M Koelle
-
依托单位:
Genomic systems approach to measure HSV-1-specific T-cell dominance in humans
-
批准号:8243351
-
项目类别:
-
资助金额:$30.47万
-
财政年份:2011
-
负责人:David M Koelle
-
依托单位:
Genomic systems approach to measure HSV-1-specific T-cell dominance in humans
-
批准号:8386576
-
项目类别:
-
资助金额:$29.12万
-
财政年份:2011
-
负责人:David M Koelle
-
依托单位:
Local Determinants of HSV-2 Shedding in Humans
-
批准号:8305101
-
项目类别:
-
资助金额:$29.46万
-
财政年份:2011
-
负责人:David M Koelle
-
依托单位:
HSV-1-specific T-cell responses in human sensory ganglia
-
批准号:7738784
-
项目类别:
-
资助金额:$18.21万
-
财政年份:2009
-
负责人:David M Koelle
-
依托单位:
HSV-1-specific T-cell responses in human sensory ganglia
-
批准号:7898561
-
项目类别:
-
资助金额:$15.06万
-
财政年份:2009
-
负责人:David M Koelle
-
依托单位:
Local Determinants of HSV-2 Shedding in Humans
-
批准号:7513499
-
项目类别:
-
资助金额:$18.1万
-
财政年份:2008
-
负责人:David M Koelle
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位:
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
-
批准号:32302080
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:宋田源
-
依托单位:
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
-
批准号:82305216
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:姚骏凯
-
依托单位:
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
-
批准号:82305171
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:吴永灿
-
依托单位: